Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,578 matching trials from the live ClinicalTrials.gov search.
Conditions
Overweight or Obesity, Atrial Fibrillation
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Phoenix, Arizona • Chicago, Illinois
Enrolling by invitation No phase listed Observational

Subspecialty Ambulatory Quality Cardiology Program

NCT07283666
Conditions
Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Atrial Fibrillation
Interventions
Apixaban, Vitamin K antagonist
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
18,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

NCT01929083
Conditions
Prolonged QT Interval in EKG and Sudden Death
Interventions
Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
AF - Atrial Fibrillation, Complication, Atrio-Esophageal Fistula
Interventions
ensoETM. Esophageal cooling during AF ablation, Esophageal temperature monitoring probe
Device
Lead sponsor
Advanced Cooling Therapy LLC, d/b/a Attune Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Naples, Florida • Overland Park, Kansas • Boston, Massachusetts + 2 more
Conditions
Heart Failure, Cardiomyopathy, Cardiac Arrhythmia
Interventions
QLV interval measurement
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
La Jolla, California
Terminated No phase listed Observational

LifeVest Post-CABG Registry

NCT01448005
Conditions
Sudden Cardiac Death, Ventricular Fibrillation, Ventricular Tachycardia, Ventricular Dysfunction, Myocardial Ischemia
Interventions
wearable defibrillator (LifeVest)
Device
Lead sponsor
Zoll Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Sacramento, California • Atlanta, Georgia • Takoma Park, Maryland + 2 more
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
Interventions
Rivaroxaban 2.5 mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida
Terminated Phase 4 Interventional Results available

Effects of Fish Oil on Post Ablation Arrhythmias

NCT00791089
Conditions
Atrial Fibrillation
Interventions
LOVAZA Omega 3-acid ethyl esters, LOVAZA, placebo
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Ventricular Tachycardia
Interventions
Radiation Therapy
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass, Platelet Transfusion, Arrythmia, Cardiac, Mortality
Interventions
Platelet Transfusion, FFP and Cryoprecipitate, PRBC and cell saver Transfusion, Factor Concentrate (Bebulin)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Day to 3 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers

Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study

NCT01747746
Conditions
Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
Interventions
Rivaroxaban, Warfarin and Enoxaparin
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ventricular Tachycardia
Interventions
Radiofrequency Ablation
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
19 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Long QT Syndrome, Familial Hypercholesterolemia, Ethics, Genetic Testing
Interventions
Direct contact of family members for cascade screening of relevant variants
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Conditions
Atrial Fibrillation, Behavior
Interventions
Corrie Virtual Atrial Fibrillation Management Program
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Tachycardia, Ventricular, Ventricular Fibrillation
Interventions
Methods for monitoring patients with ICD's
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Completed Not applicable Interventional Results available

Scripps Wired for Health Monitoring Study

NCT01975428
Conditions
Diabetes, Hypertension, Cardiac Arrhythmia
Interventions
DM Pgm + device, Control
Device · Behavioral
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
La Jolla, California
Conditions
Uncontrolled Hypertension, Atrial Fibrillation
Interventions
Boston Scientific Vessix Renal Denervation System
Device
Lead sponsor
Vivek Reddy
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Sacramento, California • Kansas City, Kansas • Boston, Massachusetts + 2 more
Completed Not applicable Interventional Results available

Inappropriate Shock Reduction wIth PARAD+ Rhythm DiScrimination

NCT01410552
Conditions
Tachycardia
Interventions
PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770
Device
Lead sponsor
MicroPort CRM
Industry
Eligibility
18 Years and older
Enrollment
1,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
27
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 23 more
Conditions
Atrial Fibrillation
Interventions
Atrial fibrillation ablation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Device-Related Thrombosis, Atrial Fibrillation, Left Atrial Appendage Occlusion
Interventions
ASA plus Clopidogrel, Genetic-Tailored AntiThrombotic Strategy, Half-Dose of novel OAC
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Austin, Texas
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Conditions
Atrial Flutter, Atrial Fibrillation
Interventions
RSD1235, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
19
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gainesville, Florida + 16 more